See also this year's filing and all EDGAR filings for this company.
PDF Report 0001724344_2021_Entasis_Therapeutics_Holdings_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS': 10, '00202 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Calc 2)': 2}} |
Graph
Absolute values for 0001724344, Entasis Therapeutics Holdings Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 60,132,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 222,000 |
| 3 | remainder_Assets | 1,204,000 |
| 4 | LiabilitiesCurrent | 8,565,000 |
| 5 | LiabilitiesNoncurrent | 704,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 13,209,000 |
| 9 | ResearchAndDevelopmentExpense | 41,022,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 3,735,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 61,558,000 |
| 1 | Liabilities | 9,269,000 |
| 2 | Expenses | 54,231,000 |
| 3 | Revenues | 3,735,000 |
| 4 | StockholdersEquity | 52,289,000 |
| 5 | NetIncome | -50,496,000 |
| 6 | ComprehensiveNetIncome | -50,496,000 |
| 7 | BaseVar | 64,396,500 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.79 |
| 9 | EconomicCapitalRatio | 2.88 |